The Pathogenesis of Expanded DLBCL Subsets

Multiplatform molecular analysis revealed clinically relevant diffuse large B-cell lymphoma subtypes that may inform future therapeutic approaches.

Diffuse large B-cell lymphoma (DLBCL) is clinically heterogeneous, with differing outcomes predicted in part by the cell of origin (COO), whether activated B-cell (ABC), germinal center B-cell (GCB), or unclassified.

Now, investigators have expanded DLBCL subtypes by analyzing frozen samples of 574 diagnostic biopsies using genome and transcriptome sequencing, deep amplicon resequencing of a 372-gene panel, and DNA copy-number analysis. Clinical outcomes were analyzed for 240 patients who had received front-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy or a similar regimen.

A summary of the derived molecular classifications of four DLBCL subtypes with selected correlates and outcomes is as fo…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

The Pathogenesis of Expanded DLBCL Subsets

Topics

Reviewing Author